Novartis Responsibility. Grant Recipient agrees that Novartis’ responsibility is solely to provide the Grant Amount. Novartis will not be liable to Grant Recipient or to any other person for the Grant Activity or the use of the Grant Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Grant Recipient to return the Grant Amount and take other corrective action if Grant Recipient breaches this Agreement.
Novartis Responsibility. Sponsorship Recipient agrees that Novartis’ responsibility is solely to provide the Sponsorship Amount and to receive the tangible benefit. Novartis will not be liable to Sponsorship Recipient or to any other person for the Sponsorship Activity or the use of the Sponsorship Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Sponsorship Recipient to return the Sponsorship Amount and take other corrective action if Sponsorship Recipient breaches this Agreement.
Novartis Responsibility. Recipient agrees that Novartis’ responsibility is solely to provide the Amount stated in Exhibit A. Novartis will not be liable to Recipient or to any other person for the Activity or the use of the Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Recipient to return the Amount and take other corrective action if Recipient breaches this Agreement.
Novartis Responsibility. Recipient agrees that Novartis’ responsibility is to provide the Amount and to provide input, competences and network to the project. Novartis will not be liable to Recipient or to any other person for the Activity or the use of the Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Recipient to return the Amount and take other corrective action if Recipient breaches this Agreement.
Novartis Responsibility. As between the Parties, Novartis shall be solely responsible in its sole discretion for regulatory activities under this Agreement, including: (a) determining the regulatory plans and strategies for the Product; (b) making all Regulatory Filings with respect to the Product, except for those that are required to be made by CBMG or its Affiliates under Applicable Law, in which case Novartis shall have the right to review and provide its written approval prior to the submission of such Regulatory Filings to the SAMR or other relevant Regulatory Authority; (c) obtaining and maintaining all Regulatory Approvals for the Product, except for those which are required to be obtained by CBMG or its Affiliates under Applicable Law, in which case Novartis shall have the right to review and give its written approval prior to the submission of any application for such Regulatory Approvals to the SAMR or other relevant Regulatory Authority; and (d) conducting all meetings with Regulatory Authorities in connection with the Development and Regulatory Approval of the Product, in each case ((a) through (d)), in the Territory. Any such activities may be performed by Novartis, its Affiliates, or its designees. Confidential Treatment Requested by Cellular Biomedicine Group, Inc IRS Employer Identification No. 00-0000000 Confidential treatment requested with respect to certain portions hereof denoted with “[***]”
Novartis Responsibility. Regardless of ownership, Novartis shall have the right, but not the obligation, at its sole expense, to prosecute and maintain worldwide any [***]. With respect to the [***], Novartis:
